{
    "clinical_study": {
        "@rank": "36689", 
        "arm_group": [
            {
                "arm_group_label": "NBI-98854", 
                "arm_group_type": "Experimental", 
                "description": "Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854.  Dose titration is performed in increments of 25 mg.  NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854\n      (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily\n      for the treatment of Tardive Dyskinesia (TD) symptoms."
        }, 
        "brief_title": "NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Tardive Dyskinesia", 
        "condition_browse": {
            "mesh_term": [
                "Dyskinesias", 
                "Movement Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, randomized, double-blind, placebo-controlled, dose-titration study to\n      evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to subject's optimal\n      dose in the range of 25 to 75 mg) compared to placebo, administered once daily (q.d.) for a\n      total of 6 weeks of treatment.  Approximately 90 medically stable male and female subjects\n      with one of the following clinical diagnoses will be enrolled: schizophrenia or\n      schizoaffective disorder with neuroleptic-induced TD; mood disorder with neuroleptic-induced\n      TD; or gastrointestinal disorder with metoclopramide-induced TD.\n\n      For subjects randomized to active treatment, the starting dose will be 25 mg NBI 98854,\n      which may be escalated in increments of 25 mg every 2 weeks to a maximum of 75 mg to achieve\n      an optimal dose of NBI-98854 for each subject"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have one of the following clinical diagnoses for at least 3 months prior to screening\n             a) schizophrenia or schizoaffective disorder; b) mood disorder; or c)\n             gastrointestinal disorder (e.g., gastroparesis, gastroesophageal reflux disease)\n\n          -  Have a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3\n             months prior to screening.\n\n          -  Be receiving a stable dose of antipsychotic medication for a minimum of 30 days\n             before study start. Subjects who are not using antipsychotic medication must have\n             stable psychiatric status.\n\n          -  Have the doses of concurrent medications and the conditions being treated be stable\n             for a minimum of 30 days before study start and be expected to remain stable during\n             the study.\n\n          -  Subjects of childbearing potential must agree to use hormonal or two forms of\n             nonhormonal birth control during the study.\n\n          -  Female subjects must not be pregnant.\n\n          -  Be in good general health and expected to complete the clinical study as designed.\n\n          -  Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).\n\n          -  Have a negative urine drug screen (negative for amphetamines, barbiturates,\n             benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and\n             study start, except for any subject receiving a stable dose of benzodiazepine.\n\n          -  Have a negative alcohol breath test at screening and study start.\n\n        Exclusion Criteria:\n\n          -  Have an active clinically significant unstable medical condition within 1 month (30\n             days) prior to screening.\n\n          -  Have a history of substance dependence or substance (drug) or alcohol abuse within\n             the 3 months before study start(nicotine and caffeine dependence are not\n             exclusionary).\n\n          -  Have a known history of neuroleptic malignant syndrome.\n\n          -  Have a significant risk of suicidal or violent behavior.\n\n          -  Receiving any excluded concomitant medication such as reserpine, metoclopramide,\n             stimulants, or tetrabenazine.\n\n          -  Receiving medication for the treatment of tardive dyskinesia.\n\n          -  Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface\n             antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a\n             history of positive result.\n\n          -  Have received an investigational drug within 30 days before screening or plan to use\n             an investigational drug (other than NBI-98854) during the study.\n\n          -  Have an allergy, hypersensitivity, or intolerance to tetrabenazine.\n\n          -  Have had previous exposure with NBI-98854."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733121", 
            "org_study_id": "NBI-98854-1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "NBI-98854", 
                "description": "25 mg capsule", 
                "intervention_name": "NBI-98854", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NBI-98854", 
                "description": "50 mg capsule", 
                "intervention_name": "NBI-98854", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 14, 2014", 
        "link": {
            "description": "Interested patients or caregivers may go to www.Kinect2Study.com to get information regarding the study and participating sites.", 
            "url": "https://www.kinect2study.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Costa Mesa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92626"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fountain Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92708"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Englewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80113"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boca Raton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33486"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33012"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33125"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60640"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Farmington Hills", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48334"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beachwood", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44122"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Middleburg Heights", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44130"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Conshohoken", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19428"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenixville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19460"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bedford", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76021"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "DeSoto", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75115"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77008"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irving", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75062"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richland", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99352"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caguas", 
                        "country": "Puerto Rico", 
                        "zip": "00725"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia", 
        "other_outcome": [
            {
                "description": "Patient Global Impression of Change (PGIC) questionnaire.", 
                "measure": "Exploratory efficacy assessment of NBI-98854 administered once daily for the treatment of tardive dyskinesia (TD) symptoms", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "description": "Tardive Dyskinesia Ratings Scale (TDRS)", 
                "measure": "Exploratory efficacy assessment  of NBI-98854 administered once daily for the treatment of tardive dyskinesia (TD) symptoms", 
                "safety_issue": "No", 
                "time_frame": "Baseline; Weeks 2 and 6"
            }
        ], 
        "overall_official": {
            "affiliation": "Neurocrine Biosciences", 
            "last_name": "Chris O'Brien, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Severity of tardive dyskinesia (TD) symptoms assessed by Abnormal Involuntary Movements Scale (AIMS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Change from Baseline, Proportion of responders based on reduction from baseline", 
                "measure": "Severity of TD symptoms assessed by AIMS", 
                "safety_issue": "No", 
                "time_frame": "Week 2"
            }, 
            {
                "description": "Change from Baseline, Proportion of responders based on reduction from baseline", 
                "measure": "Severity of TD symptoms assessed by AIMS", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "description": "Change from Baseline, Proportion of responders based on reduction from baseline", 
                "measure": "Severity of TD symptoms assessed by AIMS", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinician's perspective of the participant's overall improvement of TD symptoms over time", 
                "measure": "Clinical global impression - global improvement of TD (CGI-TD)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2 and 6"
            }, 
            {
                "description": "Proportion of subjects reporting adverse events", 
                "measure": "Number of Participants with Adverse Events following dosing with NBI-98854", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "Plasma samples will be collected and analyzed to evaluate drug and metabolite plasma concentrations.", 
                "measure": "Evaluation of plasma concentrations of NBI-98854 and metabolites following repeated daily doses of NBI-98854", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2 and 6"
            }
        ], 
        "source": "Neurocrine Biosciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neurocrine Biosciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}